Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.19 +0.47 (+1.70%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Via The Motley Fool
Topics Artificial Intelligence
2 Beaten-Down Stocks With Massive Upside Potential
Via The Motley Fool
10 Incredible Growth Stocks Poised for Long-Term Gains
Via The Motley Fool
Topics Artificial Intelligence
Got $200? 2 Biotech Stocks to Buy and Hold Forever
Via The Motley Fool
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
Why This Weight Loss Drug Company's Stock Surged Today
Via The Motley Fool
3 Growth Stocks I'm Loading Up On
Via The Motley Fool
Topics Artificial Intelligence Government
Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity
The company just initiated two Phase 3 studies of its weekly under-the-skin shot to stoke weight loss. 
Via Investor's Business Daily
What's Going On With Viking Therapeutics Stock On Wednesday?
Viking Therapeutics begins Phase 3 trials for VK2735, testing weekly injections in over 5,000 adults with obesity or type 2 diabetes over 78 weeks. 
Via Benzinga
My 5 Favorite Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Topics Artificial Intelligence Economy World Trade
Amgen Expands Development Plans For Highly Anticipated Obesity Drug
Amgen is expanding its plans for weight-loss drug, MariTide, with a trio of upcoming Phase 3 studies. 
Via Investor's Business Daily
2 Biotech Stocks to Buy Before They Soar 84% and 240%, According to Certain Wall Street Analysts
Via The Motley Fool
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Via The Motley Fool
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?
Via The Motley Fool
Topics Government
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
1 Stock Down 34% This Year to Buy and Hold
Via The Motley Fool
Could Viking Therapeutics Become the Next Eli Lilly?
Via The Motley Fool
3 Best Growth Stocks to Buy in June
Via The Motley Fool
Topics Artificial Intelligence Economy Government
Better Weight Loss Stock: Amgen or Viking Therapeutics?
Via The Motley Fool
Why Viking Therapeutics Stock Bumped 3% Higher Today
Via The Motley Fool
Novo Nordisk Sheds 4% After Ousting CEO As Eli Lilly Rivalry Slams Stock Price
Novo Nordisk said Friday it will replace its CEO, citing a sharp tumble for Novo shares amid growing competition. 
Via Investor's Business Daily
Why Weight-Loss Developer Stocks Tumbled on Tuesday
Via The Motley Fool
Topics Government
2 Monster Stocks in the Making to Buy Now and Hold for 10 Years
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Down Nearly 20%: Should You Buy the Dip on Eli Lilly?
Via The Motley Fool
Topics Earnings Government World Trade
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April
Via The Motley Fool
Why Viking Therapeutics Stock Was Victorious This Week
Via The Motley Fool
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock investors. 
Via The Motley Fool
Topics World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
23 24 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS